📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 3.2.S — the full drug substance (active ingredient) section: manufacture, characterization, control, and stability.
Why it exists. Regulators must know exactly what the active molecule is, how it is made, what impurities can arise, and how it is tested and stored. This is the chemistry backbone of the quality dossier.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH M4Q · Q6B · Q11 · Q3A(R2)/Q3C(R8)/Q3D · Q5C · Q2(R2) · Q7 (GMP)
| Field | Value |
|---|---|
| Document ID | M3-S |
| Version | 3.0 (full, expanded) |
| Standard | ICH M4Q · Q6B · Q11 · Q3A(R2)/Q3C(R8)/Q3D · Q5C · Q2(R2) · Q7 (GMP) |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]Full drug-substance section (S.1–S.7) for the GLPI-103 active pharmaceutical ingredient. Numerical values (sequence, mass, specifications, batch and stability data) are illustrative but technically representative of a lipidated synthetic-peptide GLP-1/APJ dual agonist.
No comments yet. Be the first to say something!
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | CMC | Initial detail |
| 2.0 | 2026-06-29 | CMC | Full S.1–S.7 (schematic) |
| 3.0 | 2026-06-30 | CMC | Expanded — explicit structure/MW, SPPS process & IPCs, named impurities, full specification with limits, batch & stability datasets, degradation kinetics |
| Attribute | Method | Acceptance criterion |
|---|---|---|
| Appearance | Visual | White to off-white powder |
| Identity | RP-HPLC retention + intact-mass MS + peptide map | Conforms to reference |
| Assay (anhydrous, acetate-free) | RP-HPLC (UV 214/280 nm) | 95.0–105.0% |
| Related substances — any single | RP-HPLC (stability-indicating) | ≤ 0.5% |
| Related substances — total | RP-HPLC | ≤ 2.0% |
| des-lipid impurity | RP-HPLC | ≤ 0.5% |
| High-molecular-weight species (aggregates) | SE-HPLC | ≤ 1.0% |
| Peptide content | quantitative AAA / N | 90.0–100.0% (on dried basis) |
| Acetate (counter-ion) | ion chromatography | 4.0–9.0% |
| Residual TFA | ion chromatography / ¹⁹F-NMR | ≤ 0.3% |
| Water content | Karl Fischer | ≤ 8.0% |
| Residual solvents (ACN, DCM, ether, TFA) | GC headspace | ICH Q3C limits |
| Elemental impurities | ICP-MS | ICH Q3D limits |
| Bacterial endotoxins | LAL (kinetic) | ≤ 5 EU/mg |
| Bioburden | compendial | ≤ 10 CFU/g |
| Biological potency — GLP-1R | cAMP functional cell assay | 80–125% of reference |
| Biological potency — APJ | cAMP/β-arrestin functional assay | 80–125% of reference |
Procedures validated per ICH Q2(R2) (specificity incl. forced-degradation peak purity, accuracy, repeatability/intermediate precision, linearity, range, LOD/LOQ, solution stability, robustness); details in M3-AMV.
| Batch | Scale | Assay (%) | Total RS (%) | Max single (%) | Aggregates (%) | GLP-1R potency | APJ potency | Disposition |
|---|---|---|---|---|---|---|---|---|
| DS-001 | Pilot (50 g) | 99.2 | 1.1 | 0.34 | 0.4 | 103% | 98% | Released |
| DS-002 | Pilot (50 g) | 99.5 | 0.9 | 0.28 | 0.3 | 101% | 102% | Released |
| DS-003 | Registration (2 kg) | 99.4 | 1.0 | 0.31 | 0.4 | 99% | 97% | Released |
| DS-004 | Registration (2 kg) | 99.1 | 1.2 | 0.36 | 0.5 | 104% | 101% | Released |
Limits are justified by manufacturing capability (batch data), the stability-study degradation profile, toxicological qualification of individual and total impurities (Q3A), potency–efficacy linkage, and compendial requirements; the assay and related-substance methods are stability-indicating (forced degradation: acid/base hydrolysis, oxidation H₂O₂, thermal, photolytic, all with peak-purity confirmation).
Impurity investigation (QA-003 ISS-011): an early development lot showed a des-Gly deletion-sequence impurity at 0.18% (above the identification threshold). Root cause = incomplete coupling at a sterically hindered residue. The lot was re-purified and the impurity was structurally characterised and toxicologically qualified (Q3A); CAPA changed the difficult coupling to a pre-formed dipeptide fragment and added a coupling-completion IPC (M3-CS §2), which controls the impurity to ≤0.10% in subsequent batches.
A fully characterised primary reference standard (orthogonal mass, sequence, potency, water/counter-ion) and a qualified working standard bracketed against it; requalification on a defined interval and on each new lot.
Drug substance stored in double low-density-polyethylene (LDPE) liners within an HDPE drum, with desiccant, protected from light; extractable/leachable and moisture-protection suitability demonstrated.
Stability-indicating RP-HPLC (assay, related substances) and SE-HPLC (aggregates) on registration batches:
| Condition | Time | Assay | Total RS | Aggregates | Conclusion |
|---|---|---|---|---|---|
| −20 °C (long-term) | 0 / 12 / 24 mo | 99.4 → 99.1 → 98.8% | 1.0 → 1.2 → 1.4% | 0.4 → 0.5 → 0.6% | within spec |
| 5 °C | 0 / 6 / 12 mo | 99.4 → 99.0 → 98.4% | 1.0 → 1.5 → 2.0% | 0.4 → 0.6 → 0.9% | supports excursions |
| 25 °C/60% RH (accelerated) | 0 / 3 / 6 mo | 99.4 → 98.1 → 96.9% | 1.0 → 2.4 → 3.6% | 0.4 → 1.0 → 1.7% | trend; informs handling |
Principal degradation pathways are oxidation (Met/Trp), deamidation (Asn), and aggregation, all controlled by the specification and the recommended −20 °C storage with a 24-month re-test period (full dataset in M3-STAB).